Prangenix

Redefining Cancer Diagnostics & Personalized Therapeutics

Precision tools for early detection, rare-cell profiling, and therapy design—made for real-world impact.

Oncology-Focused Diagnostics & Therapeutic Blueprinting for Personalized Care

At Prangenix Therapeutics, we are building a next-gen platform for modular diagnostics, rare-cell profiling, and therapeutic blueprinting—designed to bring clarity, control, and customization to cancer and chronic disease care.

Our goal is simple: make high-resolution molecular insight not only possible, but practical—for researchers, clinicians, and biotech innovators.

Modular Liquid & Tissue Diagnostics

 

(Upcoming Solutions)

OncoX Panel:Tissue specific key oncogenes + fusion hotspots + methylation
signatures
CardioX Panel: cardio genes + tau/amyloid cfRNA + epigenetic age clocks
ImmunoX Panel: immune regulators + cytokine cfRNA + HLA typing

Rare-Cell & qCSC Profiling

 

(Under Development)

CellCapture™: Enrichment of CTCs + qCSCs from blood & tissue biopsies
Single-Cell Discover™: High-throughput scRNA-seq to map cellular states &
biomarkers
TargetMine AI: Machine-learning pipeline to prioritize CRISPR & CAR targets

Therapeutic Blueprinting

 

(Available & Expanding)

CRISPR-Guide Design: Precision gRNA sets against qCSC-validated genes
CAR-Constructs: AI-optimized binder + signaling domain libraries
ImmunoMod™: Small-molecule & cytokine modulator screening

Our Innovative Therapeutics & Diagnostics Pipeline

At Prangenix, we are building a robust pipeline that integrates multi-omics diagnostics and therapeutics focused on quiescent cancer stem cells (qCSCs). Our programs leverage cutting-edge technologies like liquid biopsy, AI-driven biomarker discovery, single-cell sequencing, and CRISPR-based therapies to accelerate innovation in cancer care.

Corporate Responsive Table
Program Modality Stage Next Milestone
HNSCC Dx panel cfDNA / cfRNA / miRNA liquid biopsy Assay design complete 30–60 sample validation
Multi-disease Dx panel Multi-omics + AI biomarker discovery Preclinical research Candidate selection
HNSCC qCSC therapy Single-cell seq + CRISPR + AI Target ID In vitro validation
Multi-disease qCSC therapy Single-cell seq + CRISPR + AI Early research Target prioritization

Why Choose Prangenix?

Modular by Design

Our diagnostic and therapeutic platforms are built to be flexible. Choose only the targets, genes, or modules that match your specific research or clinical goals—no one-size-fits-all panels.

Built for Precision

Leveraging single-cell sequencing, AI-based target mining, and molecular-level insights, we enable more accurate, context-specific diagnostics and therapy design.

Scalable & Integrable

All our results are delivered via interactive dashboards, compatible with your EMR/LIMS systems, ensuring seamless integration into clinical workflows or research pipelines.

Partner-First Mindset

We believe innovation thrives on collaboration. Our team co-develops solutions with clinicians, hospitals, research institutes, and biotech startups across India and globally.

Join Our Innovation Ecosystem

Academic Collaborators

For co-publications, pilot studies, and translational validation.

Biotech Partners

For co-development of novel diagnostics and therapies.

Clinical Beta Testers

For validating workflows in real-world settings.

Pharma Co-Developers

For therapeutic discovery, target validation, and preclinical studies.

Precision Is Just the Beginning

At Prangenix, we’re not just developing tools—we’re designing a future where diagnosis is faster, therapies are smarter, and every patient journey is guided by molecular clarity. Our modular platforms, rare-cell profiling pipelines, and AI-powered therapeutic engines are built to evolve with science—and with you. Whether you’re a researcher, clinician, or innovator, we invite you to shape the next era of precision care by partnering with us. Because the future of medicine isn’t one-size-fits-all. It’s personal—and it’s powered by Prangenix.

Frequently Asked Questions

1. What diagnostic services does Prangenix provide?
We offer modular liquid and tissue diagnostics, custom biomarker panels, single-cell profiling, and personalized therapy reports—all tailored to oncology and chronic disease care.
2. What is a modular diagnostic panel?
Modular panels allow clinicians to choose specific genes or biomarkers (5–10 targets) for testing—customized to each patient’s needs—rather than using fixed panels.
3. Are your diagnostics suitable for head and neck cancers?
Yes. We specialize in head and neck oncology with high-sensitivity tests designed to detect key mutations, fusion genes, and epigenetic markers.
4. Can I use your services for cardiovascular or immune-related diseases?
Yes. While our core focus is cancer diagnostics, we are developing panels for cardiovascular (CardioX) and immune system profiling (ImmunoX).
5. What is your dual-track innovation model?
We offer Track 1 for liquid biopsy-based early cancer detection, and Track 2 for single-cell profiling of cancer stem cells (qCSCs) to guide therapeutic decisions and future drug design.
6. What is rare-cell profiling, and why is it important?
Rare-cell profiling isolates and analyzes cancer stem cells (qCSCs) and circulating tumor cells (CTCs)—critical for understanding relapse and drug resistance.
7. What is CellCapture™ and Single-Cell Discover™?
These are our proprietary platforms for isolating rare cells and performing high-throughput single-cell RNA sequencing to guide therapeutic strategies.
8. How are therapy blueprints generated?
Using scRNA-seq data and AI, we create therapy blueprints that guide treatment by identifying druggable targets and resistance patterns.
9. Can hospitals integrate your reports into their systems?
Yes. All results are EMR and LIMS compatible, delivered through interactive dashboards designed for seamless clinical integration.
10. Who can benefit from your services?
Oncologists, hospitals, researchers, pharma companies, and patients seeking early detection, treatment monitoring, and precision therapy planning.